AcelRx Pharmaceuticals (ACRX) Receives ‘Analyst’ Rating

AcelRx Pharmaceuticals (ACRX) : Zacks Investment Research ranks AcelRx Pharmaceuticals (ACRX) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.8, which indicates as a Buy.

AcelRx Pharmaceuticals (ACRX) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $11 and the lowest price target forecast is $3. The average forecast of all the analysts is $7.06 and the expected standard deviation is $3.37.


AcelRx Pharmaceuticals (NASDAQ:ACRX): After opening at $3.66, the stock dipped to an intraday low of $3.52 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $3.83 and the buying power remained strong till the end. The stock closed at $3.6 for the day, a gain of 9.76% for the day session. The total traded volume was 4,335,330. The stocks close on the previous trading day was $3.28.

AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Companys lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.